Repligen Corporation $RGEN Shares Bought by Congress Asset Management Co.

Key Points

• Congress Asset Management Co. increased its stake in Repligen Corporation by 18.0% during the second quarter, bringing its total ownership to 152,450 shares worth approximately $18.96 million.
• Equities analysts have given Repligen a consensus target price of $168.75, with several firms, including Evercore ISI and Royal Bank of Canada, raising their price targets for the stock.
• Repligen reported a 14.8% increase in quarterly revenue year-over-year, despite missing earnings per share estimates, with a revenue of $182.37 million for the last quarter.

Congress Asset Management Co. increased its stake in Repligen Corporation (NASDAQ:RGEN - Free Report) by 18.0% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 152,450 shares of the biotechnology company's stock after purchasing an additional 23,231 shares during the quarter. Congress Asset Management Co. owned 0.27% of Repligen worth $18,962,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD increased its stake in shares of Repligen by 6.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock valued at $962,711,000 after acquiring an additional 430,039 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Repligen during the 1st quarter worth about $35,536,000. Artemis Investment Management LLP boosted its holdings in Repligen by 110.1% in the 1st quarter. Artemis Investment Management LLP now owns 323,229 shares of the biotechnology company's stock worth $41,128,000 after acquiring an additional 169,397 shares during the period. GAMMA Investing LLC boosted its holdings in Repligen by 17,721.1% in the 1st quarter. GAMMA Investing LLC now owns 121,896 shares of the biotechnology company's stock worth $15,510,000 after acquiring an additional 121,212 shares during the period. Finally, T. Rowe Price Investment Management Inc. boosted its holdings in Repligen by 64.0% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 260,848 shares of the biotechnology company's stock worth $33,191,000 after acquiring an additional 101,791 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Evercore ISI upgraded Repligen from an "in-line" rating to an "outperform" rating and increased their target price for the company from $130.00 to $155.00 in a research note on Monday. Royal Bank Of Canada restated an "outperform" rating and set a $205.00 price objective on shares of Repligen in a research note on Tuesday, September 2nd. HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a research note on Wednesday, September 3rd. Wall Street Zen cut Repligen from a "buy" rating to a "hold" rating in a research note on Sunday, June 29th. Finally, Wells Fargo & Company reduced their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. Nine research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Repligen has an average rating of "Moderate Buy" and a consensus target price of $168.75.

Repligen Price Performance

NASDAQ:RGEN opened at $125.61 on Friday. The business's 50-day moving average price is $120.22 and its 200 day moving average price is $125.78. The firm has a market cap of $7.07 billion, a P/E ratio of -502.42, a PEG ratio of 2.24 and a beta of 1.07. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing analysts' consensus estimates of $0.40 by ($0.03). The firm had revenue of $182.37 million for the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. Repligen's quarterly revenue was up 14.8% compared to the same quarter last year. During the same period in the prior year, the company posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, sell-side analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the business's stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the completion of the acquisition, the director directly owned 1,800 shares in the company, valued at $201,834. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.20% of the stock is currently owned by company insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.